A multicenter randomized controlled trial comparing administration of antithrombin III after liver resection (HiSCO-05 trial)

2003/09/22 by Jean Boase‐Beier, Shintaro Kuroda, Tsuyoshi Kobayashi +10
Medicine · #Hepatocellular Carcinoma Treatment and Prognosis #Abdominal Surgery and Complications #Organ Transplantation Techniques and Outcomes

paper · doi:10.1016/j.surg.2021.03.057

Abstract

This study showed that the administration of antithrombin III resulted in no significant difference in preventing posthepatectomy liver failure, possibly through suppressing coagulopathy.

Related

• Comparison of Two Artificial Liver Treatments for Acute Liver Failure: A Retrospective Observational Study
• What is the optimal management of thromboprophylaxis after liver transplantation regarding prevention of bleeding, hepatic artery, or portal vein thrombosis? A systematic review of the literature and expert panel recommendations
• Effects of Inflammation on Hemostasis in Acutely Ill Patients with Liver Disease
• Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis
• Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)